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Abstract
Background: A common finding amongst patients with inhalational anthrax is a paucity of polymorphonuclear
leukocytes (PMNs) in infected tissues in the face of abundant circulating PMNs. A major virulence determinant of
anthrax is edema toxin (ET), which is formed by the combination of two proteins produced by the organism,
edema factor (EF), which is an adenyl cyclase, and protective antigen (PA). Since cAMP, a product of adenyl
cyclase, is known to enhance endothelial barrier integrity, we asked whether ET might decrease extravasation of
PMNs into tissues through closure of the paracellular pathway through which PMNs traverse.
Results: Pretreatment of human microvascular endothelial cell(EC)s of the lung (HMVEC-L) with ET decreased
interleukin (IL)-8-driven transendothelial migration (TEM) of PMNs with a maximal reduction of nearly 60%. This
effect required the presence of both EF and PA. Conversely, ET did not diminish PMN chemotaxis in an EC-free
system. Pretreatment of subconfluent HMVEC-Ls decreased transendothelial
14 C-albumin flux by ~ 50% compared
to medium controls. Coadministration of ET with either tumor necrosis factor-a or bacterial lipopolysaccharide,
each at 100 ng/mL, attenuated the increase of transendothelial
14 C-albumin flux caused by either agent alone. The
inhibitory effect of ET on TEM paralleled increases in protein kinase A (PKA) activity, but could not be blocked by
inhibition of PKA with either H-89 or KT-5720. Finally, we were unable to replicate the ET effect with either
forskolin or 3-isobutyl-1-methylxanthine, two agents known to increase cAMP.
Conclusions: We conclude that ET decreases IL-8-driven TEM of PMNs across HMVEC-L monolayers independent of
cAMP/PKA activity.
Background
Anthrax refers to those clinical syndromes caused by the
spore-forming, Gram-positive organism, Bacillus anthra-
cis [1]. Classically, anthrax presents as one of three syn-
dromes: cutaneous, gastrointestinal, and pulmonary [1].
Pulmonary anthrax is among the most feared of infec-
tious diseases; once clinical symptoms have developed,
mortality remains high even with appropriate treatment.
Much of the pathogenesis of anthrax is currently attrib-
uted to two toxins, each of which is produced from two
of three proteins synthesized by the bacillary form of
the organism: protective antigen (PA), edema factor
(EF), and lethal factor (LF) [1]. PA combines with either
LF to form lethal toxin (LT), or with EF to form edema
toxin (ET) [1]. LT received its name as it was thought
to be the principal virulence determinant responsible for
the most deleterious sequelae of anthrax infection [1].
ET was so named as it caused localized edema, in vivo,
upon subcutaneous injection [1].
The mechanisms through which ET elicits host cell
responses are incompletely understood. PA is the recep-
tor binding moiety of the toxin complex. After binding
to one of two surface receptors, endothelial marker-8
(TEM-8)/anthrax receptor 1 (ANTXR1) or capillary
morphogenesis protein-2 (CMG-2)/anthrax receptor 2
(ANTXR2), PA is cleaved into a 63 kDa fragment by
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sent in the epithelial cells lining the respiratory pathway,
skin, and gastrointestinal tract, as well as being selec-
tively upregulated in endothelial cell(EC)s during angio-
genesis and tumorigenesis [4]. In contrast, ANTXR2 is
ubiquitously expressed in most human tissues [5]. These
PA fragments oligomerize into ring-shaped heptamers,
to which EF binds [2]. The entire complex then under-
goes receptor-mediated endocytosis [2]. This endosome
is acidified, resulting in conformational changes, which
in turn, permit insertion of the multiprotein complex
comprised of EF and the PA cleavage product into the
endosomal membrane [2]. EF is then translocated to the
cytosol, where it exerts its biological effects [2]. EF is
one of four known bacterial products that are intrinsic
adenyl cyclases [6]. Its catalytic rate is 100-fold higher
than any mammalian equivalent [6]. The current under-
standing is that most of the effects of EF are due to ele-
vated levels of mislocalized cAMP [1]. ET has been
demonstrated to increase cAMP in a variety of cell
types, including Jurkat cells, Hela cells, monocytes, and
most relevant to the current studies, ECs and polymor-
phonuclear leukocyte(PMN)s [3,7-9]. cAMP is a ubiqui-
tous secondary messenger with multiple downstream
effectors, including protein kinase A (PKA) and protein
activated by cAMP (EPAC), a guanine nucleotide
exchange factor (GEF) for Ras-related protein 1 (RAP1)
[10]. There are two EPAC variants, EPAC1 and EPAC2,
each of which has a distinct domain structure and tis-
sue-specific expression [10]. The EPAC1-RAP1 pathway
has been implicated in such cellular processes as vascu-
lar endothelial (VE)-cadherin-mediated cell-cell adhesion
[11-13], integrin mediated adhesion [14], monocyte che-
motaxis [15], Ca
2+-induced exocytosis [16], and Fcg-
receptor mediated phagocytosis [17]. Whether ET might
also exert biological effects independent of cAMP is
unknown.
Highly purified, recombinant ET is lethal to mice [18]
at lower doses than is LT [19]. Curiously, edema was
absent in these mice at the microscopic level [18]. ET
suppresses the T-lymphocyte secretion of the PMN che-
moattractant, interleukin (IL)-8 [20]. ET also impairs
PMN phagocytosis and superoxide production [21]. In
EC-free systems, investigators have demonstrated that
ET increases PMN chemotaxis [22], whereas others
have shown an inhibitory effect [9]. Of relevance to the
current report, ET also decreases EC chemotaxis [7].
In 2001, renewed interest in pulmonary anthrax was
generated when 11 bioterrorism-related cases were
described [23,24]. A unifying feature of these cases was
a normal to slightly elevated circulating leukocyte count
in the face of relatively high levels of bacteremia [24].
Although circulating PMNs were abundant, lung tissues
from these patients were notable for a lack of intra-
alveolar inflammatory infiltrates [25]. The pleural fluid
of several patients contained scant PMNs. Similarly, in
African Green Monkeys exposed to anthrax spores, the
pulmonary interstitium was expanded by fibrin and
edema, but contained few PMNs [26]. These combined
data suggest an impaired delivery of circulating PMNs
to extravascular sites of infection. Since PMNs are an
essential host defense against bacterial infection, a survi-
val advantage would be conferred to any infecting
organism that could disable these phagocytic cells.
From its name, most observers would intuit that ET
increases edema formation, i.e., the paracellular passage
of fluid and macromolecules. However, agents that
increase intracellular cAMP are known to enhance EC-
EC adhesion, tighten the paracellular pathway, and pro-
mote barrier integrity [11,27-32]. He et al found that
basal levels of cAMP are necessary to maintain barrier
function under resting conditions [30]. Multiple investi-
gators have demonstrated that pharmacologic agents
which increase cAMP or behave as cAMP analogues in
ECs enhance barrier function [11,27,28,31-33]. Prior stu-
dies which have looked at ET effects on PMN chemo-
taxis have done so in EC-free systems, and therefore did
not examine whether ET might impair PMN migration
to target tissues through an effect on the endothelium.
In the current study, we have defined a novel mechan-
ism through which a bacteria-derived toxin, ET, may
indirectly, through the counter-regulation of the
endothelial paracellular pathway, impair extravasation of
PMNs into tissues.
Results
ET protects against IL-8-stimulated transendothelial
migration (TEM) of PMNs
Since ET directly stimulates ECs to increase cAMP [7],
which in turn, enhances endothelial barrier integrity
[11,27-32], we asked whether ET might decrease TEM
of PMNs. Pretreatment of monolayers of human micro-
vascular endothelial cells of the lung (HMVEC-Ls) with
ET decreased IL-8-stimulated TEM by ~ 60% (Figure
1 A ) .N e i t h e rE Fn o rP Aa l o n ew e r ea b l et or e p r o d u c e
the ET effect (Figure 1B). For these calculations, total
fluorescence associated with PMNs placed in each upper
compartment represented 100% migration while %
migration was calculated as fluorescence in the lower
compartment/fluorescence in the upper compartment ×
100%.
ET acts at the level of the EC to decrease IL-8-driven TEM
of PMNs
Since ET decreased the TEM of PMNs (Figure 1A), we
asked whether it acted directly on PMNs or indirectly
via the EC response. When PMNs were co-incubated
with ET in the absence of ECs, ET at the same
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Page 2 of 13concentration that impaired TEM (1000 ng/mL:1000 ng/
L) did not decrease IL-8-driven PMN chemotaxis com-
pared to medium controls (Figure 2A). These data indi-
cate that the ability of ET to diminish TEM of PMNs
cannot be explained through a direct effect on PMNs.
Since these PMNs were preloaded with the fluoroprobe,
calcein-AM, a known intracellular Ca
2+-binder [34], and
the host response to ET is calmodulin- and Ca2 +
-dependent [1,2,8,22], we asked whether calcein-AM
might diminish PMN responsiveness to ET. The impact
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Figure 1 Effect of ET on the TEM of PMNs.( A) Human microvascular endothelial cells from the lung (HMVEC-Ls) cultured to confluence in
assay chambers were exposed for 4 h to either increasing concentrations of ET at the indicated doses each of EF and PA (EF:PA) or medium
alone. (B) HMVEC-L monolayers cultured to confluence in assay chambers were exposed for 4 h to medium, ET (1000 ng/mL:1000 ng/mL), EF
(1000 ng/mL), or PA (1000 ng/mL). These same HMVEC-L monolayers were then inserted into the wells of 24-well plates containing either IL-8
(10 ng/mL) or medium alone, after which calcein-AM-labeled PMNs were added to the upper compartment of each chamber. After 2 h, each
lower compartment was fluorometrically assayed. Each vertical bar represents mean (+/- SEM) TEM of PMNs (%). The n for each group is
indicated in each bar. * indicates significantly increased compared to the simultaneous medium controls at p < 0.05. ** indicates significantly
decreased compared to the IL-8 stimulus alone at p < 0.05.
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Page 3 of 13of ET on IL-8 driven chemotaxis of unlabeled PMNs
was assessed. In these studies, IL-8 increased PMN che-
motaxis ~ 1.4-fold compared to the simultaneous med-
ium controls (Figure 2B). The addition of ET did not
alter PMN chemotaxis compared to PMNs incubated
with IL-8 alone. These data confirm those generated in
our studies with calcein-AM-labeled PMNs (Figure 2A)
and further support exclusion of a direct ET effect on
PMNs.
To establish whether the ability of ET to decrease IL-
8-driven TEM of PMNs was mediated indirectly through
the EC response, we measured the effect of ET on
movement of a permeability tracer across the endothelia.
In a subconfluent HMVEC-L monolayers, where the
average baseline transendothelial
14 C-albumin flux was
0.0256 (+/- 0.0147) pmol/h, ET, at increasing concentra-
tions, dose-dependently decreased mean (+/- SEM)
transendothelial
14 C-albumin flux compared to the
simultaneous medium controls (Figure 2C). ET concen-
trations as low as 100 ng/mL:100 ng/mL diminished
transendothelial
14 C-albumin flux. These data indicate
that ET restricts passage of macromolecules through the
same endothelial paracellular pathway through which
PMNs migrate. To provide additional evidence that ET
decreases IL-8-driven TEM of PMNs through the EC
response, we tested whether ET might protect against
agonist-induced barrier disruption. In confluent
HMVEC-Ls where the mean (+/- SEM) baseline trans-
endothelial
14 C-albumin flux was 0.01 (+/- 0.006)
pmol/h, both human recombinant tumor necrosis factor
(TNF)-a and bacterial lipopolysaccharide (LPS), each at
100 ng/mL, increased
14 C-albumin flux > 2-fold com-
pared to the simultaneous medium controls (Figure 2D).
When LPS and TNF-a were coadministered with ET at
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Figure 2 ET effect on IL-8-driven TEM of PMNs is due to a direct effect on ECs.( A) Naked filters mounted on chemotaxis chambers were
placed into wells containing either medium or IL-8 (10 ng/mL), after which calcein-AM-labled PMNs, suspended in medium containing ET (1000
ng/mL:1000 ng/mL) or medium alone, were added to each upper compartment. After 2 h, the contents of each lower compartment were
fluorometrically assayed. Each vertical bar represents mean (+/- SEM) chemotaxis of PMNs (%). (B) Naked filters were mounted in modified
Boyden chemotaxis chambers in which the lower compartment contained either medium or IL-8 (10 ng/mL). PMNs, suspended in medium
containing ET or medium alone, were added to each upper compartment. After 0.5 h, the filter was removed, fixed, washed, stained with crystal
violet, washed, and the top surface of each filter scraped free of cells. The crystal violet was then extracted and absorbance measured at 560
nm. Each vertical bar represents mean (+/- SEM) absorbance at 560 nm. (C) HMVEC-Ls were seeded at a density of 1.0 × 10
5 cells/assay chamber
and cultured overnight prior to treatment for 6 h with either medium or increasing concentrations of ET. Each vertical bar represents mean (+/-
SE) transendothelial
14 C-BSA flux. (D) HMVEC-Ls cultured to confluence in assay chambers were treated for 6 h with medium, TNF-a (100 ng/
mL), TNF-a in the presence of ET (1000 ng/mL:200 ng/mL), LPS (100 ng/mL), or LPS + ET (1000 ng/mL:200 ng/mL). Each vertical bar represents
mean (+/- SEM) transendothelial flux of
14 C-BSA. The n for each group is indicated in each bar. * indicates significantly increased compared to
the simultaneous medium controls at p < 0.05. ** indicates significantly decreased compared to the simultaneous medium control at p < 0.05.
*** indicates significantly decreased compared to either TNF-a or LPS alone at p < 0.05.
Nguyen et al. BMC Microbiology 2012, 12:2
http://www.biomedcentral.com/1471-2180/12/2
Page 4 of 131000 ng/mL:200 ng/mL, the increase in transendothelial
14 C-albumin flux in response to either LPS or TNF-a
was decreased by ≥ 60% and ~ 45%, respectively, com-
pared to albumin flux in response to each respective
agonist alone (Figure 2D). These data indicate that ET
provides partial protection against both endogenous
host and exogenous bacteria-derived mediators of
endothelial barrier disruption through its action on ECs.
The effect of ET on IL-8 driven TEM of PMNs is PKA-
independent
Since ET is an adenyl cyclase that increases cAMP, we
asked whether the ability of ET to diminish TEM of
PMNs might be mediated through EC-generated PKA.
First, ET was tested for its ability to increase PKA activ-
ity in HMVEC-Ls. ET at 1000 ng/mL:1000 ng/mL,
increased PKA activity (Figure 3A). When ECs were
exposed for increasing times (0-24 h) to a fixed concen-
tration of ET (1000 ng/mL:1000 ng/mL), PKA activity
was increased at 6 h, returning to basal levels at ≤ 24 h
(Figure 3B). Two structurally dissimilar PKA inhibitors,
H-89 and KT-5720, were then tested for their ability to
counteract the ET effect on TEM. To confirm that H-89
and KT-5720 impaired PKA activity in HMVEC-Ls, we
examined ET-induced phosphorylation of cAMP
response element-binding protein (CREB), a direct PKA
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Figure 3 ET activates PKA in HMVEC-Ls. HMVEC-Ls were seeded onto 10 cm plates and allowed to reach 80-90% confluence prior to (A)6h
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significantly increased compared to the simultaneous medium controls at p < 0.05.
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Page 5 of 13substrate [35]. Initially, phospho-CREB (pCREB) signal
was normalized to total CREB. However, stripping of
the anti-pCREB antibody was incomplete and inconsis-
tent. Consequently, pCREB was normalized to b-tubulin.
H-89 and KT-5720 each diminished ET-induced CREB
phosphorylation (Figure 4A, lanes 3 vs 2, 6 vs 5). Quan-
titative densitometry was performed on each of these
same blots. H-89 and KT-5720 both completely blocked
phosphorylation of CREB normalized to b-tubulin com-
pared to the simultaneous medium controls (Figure 4B),
indicating their effectiveness as inhibitors of PKA in
HMVEC-Ls. In these experiments, IL-8 (10 ng/mL)
i n c r e a s e dT E Mo fP M N s~4 - f o l dw h e nc o m p a r e dt o
simultaneous medium controls (Figure 4C).
Pretreatment of ECs with either H-89 (10 μM) or KT-
5720 (10 μM) alone had no effect on TEM in the pre-
sence or absence of IL-8 (data not shown). Pretreatment
of ECs with ET (1000 ng/mL:1000 ng/mL) decreased IL-
8-driven TEM of PMNs by ~ 45%. H-89 and KT-5720
each failed to reverse the ET effect; i.e., the effect of
either agent co-administered with ET was not signifi-
cantly different than ET alone (Figure 4C). Although H-
89 and KT-5720 each completely blocked ET-induced
increments in PKA activity as measured by pCREB/b-
tubulin ratios (Figure 4B), these same inhibitors had no
impact on the ET-induced reduction of TEM (Figure
4C). Taken together, these data do not support a PKA-
mediated ET effect on TEM.
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Figure 4 ET Inhibition of TEM in the Presence of PKA Inhibitors.( A) HMVEC-Ls were preincubated in the presence (+) or absence (-) of H-89
(10 μM) or KT-5720 (10 μM), respectively, before being treated with ET (1000 ng/mL:1000 ng/mL) for 6 h and lysed. The lysates were processed
for pCREB immunoblotting. To control for protein loading and transfer, blots were stripped and reprobed for b-tubulin. IB, immunoblot, IB*,
immunoblot after stripping. (B) The pCREB signals in each blot described in (A) were quantified by densitometry of pCREB and normalized to b-
tubulin signal in the same lane in the same blot. (C) HMVEC-Ls cultured to confluence in assay chambers were pretreated with medium, H-89
(10 μM) or KT-5720 (10 μM), after which they were treated for 4 h with medium, ET, ET with H-89, or ET with KT-5720. The HMVEC-L monolayers
were then inserted into wells containing either medium or IL-8 (10 ng/mL), after which calcein-AM-labeled PMNs were added to the upper
compartment of each chamber. After 2 h, the contents of each lower compartment were fluorometrically assayed. Each vertical bar represents
mean (+/- SEM) TEM of PMNs (%). The n for each group is indicated in each bar. * indicates significantly increased compared to the
simultaneous medium only controls at p < 0.05. ** indicates significantly decreased compared to IL-8 alone at p < 0.05.
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Page 6 of 13Forskolin (FSK) and 3-isobutyl-1-methylxanthine (IBMX)
fail to reproduce the ET effect on IL-8-driven TEM of
PMNs
To provide further evidence that ET does not decrease
TEM of PMNs through cAMP or PKA activity, two dis-
tinct interventions known to increase cAMP, FSK and
IBMX, each were introduced. To confirm that FSK and
IBMX increased PKA activity in HMVEC-Ls, we first
examined FSK- and IBMX- stimulated phosphorylation
of CREB at 6 h (Figure 5A). FSK (10 μM) and IBMX (1
mM) each increased phosphorylation of CREB normal-
ized to b-tubulin when compared to the simultaneous
medium control (Figures 5B). Previous investigators
have demonstrated that FSK and IBMX cause maximal
increases of cAMP at 0.5 h with a decrease by 4 h [36];
in our studies, phosphorylation of CREB normalized to
b-tubulin was elevated but not significantly different
from the effect at the later time point (Additional File 1:
Figure S1A, B). Next, we investigated the effects of FSK
and IBMX on IL-8-driven TEM. In these experiments,
IL-8 (10 ng/mL) increased TEM of PMNs ~ 6-fold com-
pared to simultaneous medium control (Figure 5C). Pre-
treatment of ECs with ET decreased TEM of PMNs by
~ 50%. Neither FSK nor IBMX could reconstitute the
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Figure 5 Agents that increase intracellular cAMP do not reproduce the ET effect on IL-8-driven TEM of PMNs.( A)H M V E C - L sw e r e
treated for 6 h with ET (1000 ng/mL:1000 ng/mL), FSK (10 μM), IBMX (1 mM), or medium alone, and lysed. The lysates were processed for
pCREB immunoblotting. To control for protein loading and transfer, blots were stripped and reprobed for b-tubulin. IB, immunoblot, IB*,
immunoblot after stripping. (B) The pCREB signals in each blot described in (A) were quantified by densitometry and normalized to b- tubulin
signal in the same lane in the same blot. (C) HMVEC-Ls cultured to confluence in assay chambers were treated for 4 h with medium, ET, FSK, or
IBMX. These same chambers were then inserted into wells of 24-well plates containing either medium or IL-8 (10 ng/mL), after which calcein-
AM-labeled PMNs were added to the upper compartment of each chamber. After 2 h, the contents of each lower compartment were
fluorometrically assayed. Each vertical bar represents mean (+/- SEM) TEM of PMNs (%). The n for each group is indicated in each bar. * indicates
significantly increased compared to the simultaneous medium controls at p < 0.05. ** indicates significantly decreased compared to IL-8 alone at
p < 0.05.
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(Additional File 1: Figure S1C) or at 4 h (Figure 5C).
Although FSK and IBMX each upregulated PKA activity
comparable to that seen after ET treatment (Figure 5B),
none could decrease TEM (Figure 5C). Again, these
combined data do not support a cAMP/PKA-dependent
mechanism through which ET inhibits TEM of PMNs.
Discussion
In our studies, we have found that ET decreases IL-8-
driven TEM of PMNs across human lung microvascular
endothelia. We asked whether the observed ET effect
could be attributed to action on either the PMN and/or
endothelium. We found that ET blocked TEM even
when PMNs were not directly exposed to ET (Figure
1A) and required the presence of both EF and PA (Fig-
ure 1B). At the same concentrations, ET did not inhibit
PMN chemotaxis in an EC-free system (Figure 2A, B).
In contrast, we found that ET decreased
14 C-albumin
flux across preconfluent endothelia (Figure 2C). Further,
ET attenuated the increase in
14 C-albumin flux pro-
voked by both endogenous (TNF-a) and exogenous
(LPS) mediators of barrier disruption (Figure 2D). Prior
inhibition of PKA with H-89 or KT-5720 did not reverse
the ET effect on TEM (Figure 4C), and agents demon-
strated to elevate intracellular levels of cAMP in
HMVEC-Ls (Figure 5A, B, Additional File 1: Figure
S1A, B) could not reconstitute the ET effect (Figure 5C,
and Additional File 1: Figure S1C). These combined
data indicate that ET diminishes TEM of PMNs at the
level of the endothelial paracellular pathway and does so
independent of via cAMP/PKA activity.
Several studies have examined the direct effect of ET
on in vitro PMN function. O’Brien et al found that ET
inhibited PMN phagocytosis of opsonized B. anthracis
[21]. Pretreatment of PMNs with ET profoundly
reduced superoxide production in response to either
LPS or muramyl dipeptide. Crawford et al demon-
strated that ET impaired PMN NADPH oxidase activa-
tion and downstream N-formyl-methionine-leucine-
phenylalanine (fMLP)-induced superoxide production
[37]. Taken together, these studies indicate that ET
down-regulates PMN phagocytic and oxidative func-
tions. Other studies have focused on the impact of ET
on PMN chemotaxis and migration [9,22]. In the cur-
rent studies, ET did not alter the PMN chemotactic
response to IL-8 in an EC-free system (Figure 2A). To
address concerns that calcein is a Ca
2+-binder and
would interfere with any Ca
2+-mediated ET effect,
these experiments were performed in the absence of
the fluoroprobe. Even in the absence of calcein, ET
had no effect on IL-8 chemotaxis of PMNs (Figure
2B). Chemotaxis was not as vigorous in the latter
experiment, and this may be secondary to differences
in methodology; mainly the use of a modified Boyden
chambers, a shorter incubation time, as well as a dif-
ferent means of measuring PMN migration.
Wade et al found that ET stimulated directed neutro-
phil migration without having any effect on unstimu-
lated random migration [22]. They also found that
although ET increased cAMP in PMNs, the absolute
level of that increase was < 1% of that caused by the
Bordetella pertussis toxin. In contrast, Szarowicz et al
found that ET reduces chemoattractant-stimulated PMN
actin assembly, chemokinesis, chemotaxis and polariza-
tion [9]. In PMNs, ET provoked a > 50-fold increase in
cAMP and a 4-fold increase in PKA phosphorylation.
The differences between our findings and these other
reports may be attributed to dissimilar techniques. For
instance, Wade et al measured chemotaxis of PMNs
preincubated for 1 h with ET in an agarose-gel based
system, both of which were EC-free [22], whereas Szaro-
wicz’s group utilized video microscopy to study adher-
ence of PMNs preincubated for 2 h with ET to a
fibronectin-coated surface [9]. To our knowledge, none
of these previous reports studied PMN migration in the
context of the endothelial paracellular pathway. Another
potential explanation for these disparities may be due to
differences in potency of various EF preparations and
their abilities to generate cAMP. Of note, the EF pre-
paration offered by List Biologics is the least potent
(personal communication, Dr. Erik Hewlett, University
of Virginia, Charlottesville).
Far less is known about the direct effect of ET on ECs.
Hong et al demonstrated that ET reorganizes the cytos-
keleton and inhibits chemotaxis of human microvascular
ECs [7]. Tessier’s group found that ET induces a gradual
increase in transendothelial electrical resistance (TEER)
across human umbilical vein EC monolayers cultured on
collagen-coated inserts. They concluded that ET-
induced edema could not be accounted for by the direct
effect of ET on the endothelium [38]. Of interest, in our
experimental systems for both TEM of PMNs and trans-
endothelial
14 C-albumin flux, the ECs were similarly
cultured on collagen-impregnated filters. Although Tes-
sier et al studied TEER, their experiments did not
include transendothelial flux of a permeability tracer or
TEM of PMNs.
ET is an intrinsic adenyl cyclase that increases cAMP
[1]. Data exists to support a cAMP-mediated mechanism
underlying the ET effect on TEM of PMNs. Moy et al
found that cAMP agonists attenuated the ability of
thrombin to increase permeability [27]. Similarly, Fuku-
hara et al found that cAMP agonists decreased cell per-
meability and enhanced vascular EC-EC adhesion [11].
In ECs, cAMP targets multiple downstream signaling
molecules that might promote endothelial barrier integ-
rity, including PKA [39] and EPAC1 [40,41].
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shown to inhibit myosin-based contractility through
phosphorylation of myosin-light-chain-kinase, thereby
decreasing its activity [10]. PKA also inhibits RhoA
activity, stabilizes microtubules, reorganizes cortical
actin and strengthens tight junctions through phosphor-
ylation of vasodilator stimulated protein (VASP) [10]. In
our studies, we found that ET activates PKA in
HMVEC-Ls in a dose- and time- dependent manner
(Figure 3A, B). Although ET increases EC PKA activity,
its inhibitory effect on TEM could not be ascribed to
PKA activity. Two structurally dissimilar pharmacologic
inhibitors of PKA, H-89 and KT-5720, each failed to
attenuate the ET-induced decrease in IL-8-driven TEM
of PMNs (Figure 4C). Further, we were unable to repro-
duce the ET effect on TEM with either of two structu-
rally and functionally distinct pharmacologic agents each
known to increase cAMP, FSK or IBMX (Figure 5C).
Taken together, these data indicate that the mechanism
through which ET counter-regulates IL-8-driven TEM
of PMNs cannot be explained solely through cAMP/
PKA activation.
Another downstream target for cAMP is EPAC1,
which is a GEF for the ras GTPase, RAP1 [10]. Like
PKA activity, the EPAC1-RAP1 pathway also enhances
endothelial barrier function [11,12,42-44]. The EPAC1-
specific analog 8CPT-2’O-Me-cAMP, which directly
activates EPAC1 while bypassing PKA, has been shown
to decrease permeability of endothelial cell monolayers,
an effect which is ablated by prior siRNA-induced
EPAC1 knockdown [12]. Birukova et al [44] and Fuku-
hara et al [11] both demonstrated that activation of
EPAC1 attenuated thrombin-induced increases in per-
meability. As in the case of PKA, the mechanism(s) by
which EPAC1 improves barrier function is still being
elucidated. Potential EPAC1 targets include activation of
VASP, as well as activation of ARAP3, which in turn is
a GEF for RhoA, and vinculin, which supports EC-EC
adherens junctions through association with a-catenin
[10]. As PKA inhibition did not impair the ET effect on
TEM (Figure 4C), one potential pathway is through
EPAC1-RAP1 and its effectors.
Since ET evokes biological responses in both PMNs
and ECs, it was unclear as to whether the ability of ET
to regulate TEM of PMNs could be ascribed to its
impact on PMNs, ECs, or both. Although prior studies
had demonstrated that ET directly influenced PMN che-
motaxis, in our experiments, it did not (Figure 2A).
Further, ET diminished TEM of PMNs never exposed to
ET (Figure 1A). Finally, not only did ET decrease the
paracellular movement of PMNs (Figure 1A), but of a
permeability tracer as well (Figure 2B, C). These com-
bined data indicate that ET counter-regulates PMN dia-
pedesis exclusively through its effects on the
endothelium. Further support of this concept is offered
by Wittchen et al, who reported direct activation of
RAP1 in EC monolayers decreased both their permeabil-
ity as well as TEM of leukocytes [43].
Conclusions
In conclusion, we have found that anthrax-derived ET
impedes IL-8 driven movement of PMNs across an EC
monolayer, as well as attenuates the increase of transen-
dothelial
14 C albumin flux induced by TNF-a and LPS,
likely as a direct effect of ET on EC-EC adhesion. This
ability to counter-regulate paracellular pathway function
could not be ascribed to cAMP/PKA activity. Whether
this novel pathophysiology for anthrax can be extended
to other pathogenic bacteria and their toxins requires
further study.
Methods
Reagents
H-89 and KT-5720 in-solution were purchased from
Calbiochem (Gibbstown, NJ). LPS derived from E. coli
0111:B4, FSK, and IBMX were purchased from Sigma
(St. Louis, MO). EF and PA were purchased from List
Biologics (Campbell, CA). Human TNF-a was pur-
chased from R&D Systems, Inc. (Minneapolis, MN). Bio-
tinylated rabbit monoclonal anti-pCREB, murine
monoclonal anti-CREB antibodies, horseradish peroxi-
dase (HRP)-conjugated streptavidin, HRP-conjugated
goat anti-rabbit IgG, and HRP-conjugated horse anti-
murine IgG antibodies were purchased from Cell Signal-
ing Technology (Danvers, MA). Unconjugated murine
monoclonal anti-b-tubulin was purchased from Invitro-
gen (Carlsbad, CA).
EC culture
Human microvascular endothelial cells from the lung
(HMVEC-Ls), purchased from Promocell (Heidelberg,
Germany) were cultured in EC growth medium MV-2
(Promocell) containing 5% fetal bovine serum, human
recombinant epidermal growth factor (5 ng/mL), human
recombinant insulin-like growth-factor-1 (20 ng/mL),
human basic fibroblast growth factor (10 ng/mL), vascu-
lar endothelial growth factor (0.5 ng/mL), hydrocorti-
sone (0.2 μg/mL), ascorbic acid (1 μg/mL), gentamicin
(30 μg/mL), and amphotericin B (15 ng/mL) [45]. Only
ECs in passages 6-8 were studied.
Preparation and fluorescent labeling of PMNs
Whole peripheral blood from healthy human volunteers
was collected under a protocol approved by the Univer-
sity of Maryland, Baltimore, Institutional Review Board,
into acid citrate dextran (Sigma) solution, and PMNs
were isolated by dextran erythrocyte sedimentation and
density gradient centrifugation through Ficoll-Hypaque
Nguyen et al. BMC Microbiology 2012, 12:2
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pended in Hank’s balanced salt solution (HBSS) without
divalent cations (HBSS
-)a t5×1 0
5 PMNs/ml and were
incubated with 5 μM calcein-AM (Invitrogen) for 30
min at 37°C [46]. PMNs were washed three times with
HBSS
- after which their purity was > 95% and viability
98% by trypan blue dye exclusion. PMNs were resus-
pended in HBSS with divalent cations (HBSS
+)i m m e d i -
ately prior to use.
Assay for TEM of PMNs
TEM of PMNs was assayed as previously described [46].
Briefly, gelatin-impregnated polycarbonate filters (13
mm diameter, 3 μm pore size; Nucleopore, Pleasanton,
CA) were mounted in polysterene chemotactic cham-
bers (ADAPS, Dedham, MA), and sterilized overnight
with UV irradiation. These chambers, which serve as the
upper compartment for each assay chamber, were
inserted into the wells of 24-well plates, each well ser-
ving as the lower compartment of the assay chamber
and containing 1.5 mL of medium. Each upper compart-
ment was seeded with 2.0 × 10
5 HMVEC-Ls/chamber in
0.5 mL and cultured to confluence (48 h, 37°C, 5%
CO2). The EC monolayers cultured on filter supports
were treated for 4 h with either ET at increasing con-
centrations or medium alone. In other experiments, the
EC monolayers were treated for either 0.5 h or 4 h with
either FSK (10 μM), IBMX (1 mM), or medium alone.
These same chambers were then inserted into wells con-
taining IL-8 (10 ng/mL) or medium alone. Calcein-AM-
labeled PMNs (5 × 10
5 cells/well) were introduced into
the upper compartments of assay chambers, incubated
for 2 h at 37°C, after which time the contents of each
lower compartment were fluorometrically assayed in a
Thermo Scientific Fluoroskan Ascent fluorometer (exci-
tation 485 nm, emission 530 nm). The fluorescence of 5
×1 0
5 calcein-AM labeled PMNs was used to generate
total fluorescence. % TEM was expressed as fluorescence
signal in the lower chamber/total fluorescence signal in
the upper compartment × 100%.
Chemotaxis of PMNs
Chemotaxis of PMNs was assayed as described [47].
Briefly, gelatin-impregnated polycarbonate filters were
mounted in chemotactic chambers, and the chambers
inserted into the wells of 24-well plates containing IL-
8 (10 ng/mL) or medium alone, as described above.
Calcein-AM-labeled PMNs (5 × 10
5 cells/well) were
suspended in either medium alone versus medium
containing increasing concentrations of ET before
being placed into the upper compartment of assay
chambers and incubated for 2 h at 37°C. The lower
compartment was then sampled and fluorometrically
assayed. The fluorescence of 5 × 10
5 calcein-AM-
labeled PMNs was used to generate total fluorescence.
% chemotaxis was then expressed as fluorescence sig-
nal in the lower chamber/total fluorescence signal in
the upper compartment × 100%. In other experiments,
unlabeled PMNs were introduced into the upper com-
partment of a modified Boyden chemotaxis chamber
(Neuroprobe Inc., Gaithersburg, MD) while each lower
compartment contained IL-8 (10 ng/mL). After 0.5 h,
filters were removed, fixed, and washed. PMNs adher-
ent to filters were stained with crystal violet, washed
again, and the top surface of each filter scraped free of
stained PMNs. The crystal violet was then extracted
from each filter with 0.1 M citric acid in 50% ethanol
for 5 min and the A560 nm of extracts measured, as
described [48].
Assay of transendothelial albumin flux
Transendothelial
14 C-bovine serum albumin (BSA)
flux was assayed as described [45], with minor modifi-
cations. Briefly, gelatin-impregnated polycarbonate fil-
ters (13 mm diameter, 0.4 μmp o r es i z e )w e r e
mounted on chemotactic chambers, sterilized, and
inserted into the wells of 24-well plates. HMVEC-Ls
were cultured in the upper compartment of each assay
chamber. The baseline barrier function of each mono-
layer was established by introducing an equivalent con-
centration of the permeability tracer,
14 C-BSA (1.1
pmol, i.e., 4800-6200 dpm/0.5 ml) (Sigma; St. Louis,
MO), to each upper compartment for 1 h, after which
0.5 ml from the lower compartment was mixed with
4 . 5m lo fO p t i f l u o rS c i n t i l l a t i o nf l u i d( P a c k a r dI n s t r u -
ments, Downers Grove, IL) and counted in a liquid
scintillation counter (Beckman, Fullerton, CA). In
selected experiments, ECs were seeded at 1 × 10
5
cells/chamber and cultured overnight to 80-90% con-
fluence. Here, monolayers were cultured to subconflu-
ence because baseline permeability in postconfluent
monolayers was so low as to make detection of any
further decreases difficult to measure in our assay sys-
tem. The monolayers were then exposed for 6 h to
increasing concentrations of ET, each with a fixed
r a t i oo fE Ft oP Ao f1n g / m L : 1n g / m L ,o rm e d i u m
alone, after which transendothelial
14 C-BSA flux was
assayed. In other experiments, ECs were seeded at 2 ×
10
5 cells/chamber and cultured to confluence over 48
h. The baseline barrier function of each monolayer was
established and only those chambers which retained ≥
97% of the permeability tracer were studied. The
monolayers were then exposed for 6 h to LPS (100 ng/
mL), TNF-a (100 ng/mL), either LPS or TNF-a in the
presence of increasing concentrations of ET, with a
fixed ratio of EF to PA of 5 ng/mL:1 ng/mL, or med-
ium alone. Transendothelial
14 C-BSA flux was again
assayed and was expressed in pmol/h.
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PKA activity was measured in HMVEC-Ls using an
ELISA (Stressgen, Plymouth Meeting, PA) for the
screening of activators and inhibitors of PKA, according
to the manufacturer’s instructions [49]. Briefly,
HMVEC-Ls were seeded into 10 cm dishes and cultured
to 80-90% confluence. The pharmacological agent of
interest was added for the indicated time, after which
cells were lysed. The lysates were then added to the
microtiter plate, whose wells were pre-coated with a
substrate that can be phosphorylated by PKA. ATP was
added and the reaction was allowed to proceed for 90
min at 30°C. The contents of each well were decanted
before rabbit polyclonal antibody specific for the phos-
phorylated PKA substrate was added. The plate was
incubated for 60 min at room temperature, washed four
times, incubated for 30 min with HRP-conjugated anti-
rabbit IgG, again washed, and incubated with tetra-
methylbenzidine (TMB) substrate. After 1 h, the stop
solution was added and A450 nm measured. A standard
curve was generated using purified PKA provided by the
manufacturer.
pCREB, CREB, and b-tubulin immunoblotting for PKA
activity
Postconfluent HMVEC-Ls were exposed to ET (1000
ng/mL:1000 ng/mL), ET + H-89 (10 μM), ET + KT-
5720 (10 μM), FSK (10 μM), IBMX (1 mM), or medium
alone, after which they were lysed with ice-cold modi-
fied radioimmunoprecipitation assay buffer, containing
50 mM Tris-HCl, pH 7.4, 1% Nonidet P-40, 0.25%
sodium deoxycholate, 150 mM NaCl, 1 mM EGTA, 100
mg/ml type-1 DNase, 1 mM sodium orthovanadate, 1
mM NaF, 1 mg/ml pepstatin A, 10 mM pyrophosphate,
and 1 mM phenylarsine oxide (all purchased from
Sigma), and 1 tablet of complete protease inhibitor mix-
ture (Roche Applied Science) per 20 ml of lysate as
described [50]. The lysates were centrifuged, and the
supernatants were assayed for protein concentration
with a Bradford protein assay kit (Bio-Rad). The samples
were resolved by 8-16% gradient SDS-PAGE and trans-
ferred onto PVDF membranes. The blots were blocked
with membrane blocking solution (Zymed Laboratories
Inc., San Francisco, CA) and were incubated with bioti-
nylated rabbit anti-pCREB antibodies (Cell Signaling),
followed by streptavidin HRP (Cell Signaling), after
which they were developed with enhanced chemolumi-
nescence (ECL). To control for protein loading and
transfer, the blots were stripped and reprobed with
either murine anti-CREB and/or murine anti-b-tubulin
(Invitrogen), and each pCREB band was normalized to
total CREB and/or b-tubulin signal in the same lane on
the same blot.
Statistics
One-way analysis of variance, followed by post hoc com-
parisons using Tukey-Kramer’sm u l t i p l ep a i r w i s ec o m -
parison test, was used to compare the mean responses
among experimental and control groups for all experi-
ments. SAS 9.2 was used for the analyses (SAS Institute
Inc., Cary, NC, USA). A p value of < 0.05 was consid-
ered significant.
Additional material
Additional file 1: Figure S1. FSK and IBMX do not reproduce the ET
effect on IL-8-driven TEM of PMNs at 0.5 h. (A) HMVEC-Ls were treated
for 0.5 h with FSK (10 μM), IBMX (1 mM), or medium alone, and lysed.
The lysates were processed for pCREB immunoblotting. IB, immunoblot,
IB*, immunoblot after stripping. To control for protein loading and
transfer, blots were stripped and reprobed for b-tubulin. (B) The pCREB
signals in each blot described in (A) were quantified by densitometry
and normalized to b-tubulin signal in the same lane in the same blot. (C)
HMVEC-Ls cultured to confluence in assay chambers were treated for 0.5
h with medium, FSK, or IBMX. These same chambers were then inserted
into wells of 24-well plates containing either medium or IL-8 (10 ng/mL),
after which calcein-AM-labeled PMNs were added to the upper
compartment of each chamber. After 2 h, the contents of each lower
compartment were fluorometrically assayed. Each vertical bar represents
mean (+/- SEM) TEM of PMNs (%). The n for each group is indicated in
each bar. * indicates significantly increased compared to the
simultaneous medium controls at p < 0.05. ** indicates significantly
decreased compared to IL-8 alone at p < 0.05.
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